Literature DB >> 10586011

Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants.

S M Bülow1, M Nir, E Levin, B Friis, L L Thomsen, J E Nielsen, J C Holm, T Moller, M E Bonde-Hansen, H E Nielsen.   

Abstract

OBJECTIVE: To evaluate the effect of systemic prednisolone as an adjunct to conventional treatment with beta2-agonist, respiratory support, and fluid replacement in hospitalized infants <24 months of age with respiratory syncytial virus (RSV) infection.
METHODS: The study was randomized, double-blind, and placebo-controlled. During the winter of 1995-1996, 147 infants <2 years of age, hospitalized with RSV infection, were allocated to treatment with either systemic prednisolone mixture 2 mg/kg daily or placebo for 5 days. MAIN OUTCOME MEASURES: The acute effect variables were duration of stay in hospital, use of medicine, and supportive measures while in hospital. At follow-up 1 month after discharge, the acute effect variables were duration of illness, start in day care center, morbidity, and use of medicine. At follow-up 1 year after discharge, the acute effect variables were morbidity, use of medicine, and skin prick tests with allergens.
RESULTS: Prednisolone treatment had no effect on any of the outcome measures.
CONCLUSIONS: Our randomized prospective study in infants hospitalized with acute RSV infection showed no effect of systemic prednisolone treatment either in the acute state of RSV infection, nor in the follow-up 1 month and 1 year after admission to hospital. We find our results in agreement with the largest studies reported earlier; therefore, corticosteroid, whether by the systemic route or by inhalation, should not be prescribed to infants with RSV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586011     DOI: 10.1542/peds.104.6.e77

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

Review 1.  Pathogenesis of respiratory syncytial virus infection in the murine model.

Authors:  R Stokes Peebles; Barney S Graham
Journal:  Proc Am Thorac Soc       Date:  2005

2.  The respiratory syncytial virus (RSV) nonstructural proteins mediate RSV suppression of glucocorticoid receptor transactivation.

Authors:  Jeanette I Webster Marketon; Jacqueline Corry; Michael N Teng
Journal:  Virology       Date:  2013-11-26       Impact factor: 3.616

3.  Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis.

Authors:  Avraham Beigelman; Megan Isaacson-Schmid; Geneline Sajol; Jack Baty; Oscar M Rodriguez; Erin Leege; Kevin Lyons; Toni L Schweiger; Jie Zheng; Kenneth B Schechtman; Mario Castro; Leonard B Bacharier
Journal:  J Allergy Clin Immunol       Date:  2014-11-18       Impact factor: 10.793

4.  Rhinovirus-associated wheeze during infancy and asthma development.

Authors:  Tuomas Jartti; James E Gern
Journal:  Curr Respir Med Rev       Date:  2011-06-01

Review 5.  Glucocorticoids for acute viral bronchiolitis in infants and young children.

Authors:  Ricardo M Fernandes; Liza M Bialy; Ben Vandermeer; Lisa Tjosvold; Amy C Plint; Hema Patel; David W Johnson; Terry P Klassen; Lisa Hartling
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

6.  Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema.

Authors:  Pasi Lehtinen; Aino Ruohola; Timo Vanto; Tytti Vuorinen; Olli Ruuskanen; Tuomas Jartti
Journal:  J Allergy Clin Immunol       Date:  2006-12-27       Impact factor: 10.793

7.  The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial.

Authors:  Marieke J J Ermers; Maroeska M Rovers; Job B van Woensel; Jan L L Kimpen; Louis J Bont
Journal:  BMJ       Date:  2009-03-31

8.  Pharmacological management of acute bronchiolitis.

Authors:  Melvin Wright; Charles J Mullett; Giovanni Piedimonte
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

9.  The azithromycin to prevent wheezing following severe RSV bronchiolitis-II clinical trial: Rationale, study design, methods, and characteristics of study population.

Authors:  Mythili Srinivasan; Leonard B Bacharier; Charles W Goss; Yanjiao Zhou; Jonathan Boomer; Sarah Bram; Dana Burgdorf; Carey-Ann Burnham; Timothy Casper; Mario Castro; Andrea Coverstone; Matthew Haslam; Watcharoot Kanchongkittiphon; Cadence Kuklinski; Qinghua Lian; Kenneth Schechtman; Gregory A Storch; Kelly True; Meghan A Wallace; Huiqing Yin-DeClue; Elizabeth Ahrens; Jinli Wang; Avraham Beigelman
Journal:  Contemp Clin Trials Commun       Date:  2021-06-09

10.  Efficacy of prednisolone in children hospitalized for recurrent wheezing.

Authors:  Tuomas Jartti; Pasi Lehtinen; Timo Vanto; Tytti Vuorinen; Jaakko Hartiala; Heikki Hiekkanen; Pekka Malmberg; Mika Mäkelä; Olli Ruuskanen
Journal:  Pediatr Allergy Immunol       Date:  2007-06       Impact factor: 6.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.